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ABSTRACT 36 
 37 
The extracellular matrix (ECM) is a major component of the tumor microenvironment, 38 
contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In 39 
multiple myeloma (MM), interactions between MM cells and the bone marrow (BM) 40 
microenvironment, including the BM ECM, are critical to the pathogenesis of the disease and 41 
the development of drug resistance. Nevertheless, composition of the ECM in MM and its 42 
role in supporting MM pathogenesis has not been reported. We have applied a novel 43 
proteomic-based strategy and defined the BM ECM composition in patients with monoclonal 44 
gammopathy of undetermined significance (MGUS), newly diagnosed and relapsed MM 45 
compared to healthy donor-derived BM ECM. In this study, we show that the tumor ECM is 46 
remodeled at the mRNA and protein level in MGUS and MM to allow development of a 47 
permissive microenvironment. We further demonstrate that two ECM-affiliated proteins, 48 
ANXA2 and LGALS1, are more abundant in MM and high expression is associated with a 49 
decreased overall survival. This study points to the importance of ECM remodeling in MM 50 
and provides a novel proteomic pipeline for interrogating the role of the ECM in cancers with 51 
BM tropism. 52 
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INTRODUCTION 69 
 3
 70 
Multiple myeloma (MM) is a plasma cell malignancy and accounts for approximately 10% of 71 
all hematological cancers (1). MM provides a model for the study of cancer cell metastasis as 72 
MM cells are known to traffic to distant bone marrow (BM) niches via hijacking the normal 73 
processes of cellular metastasis (2). Progression of the disease is mediated by intrinsic factors 74 
of the clonal cells along with factors that mediate a permissive tumor microenvironment (3). 75 
The MM tumor niche comprises the components of the BM microenvironment - cellular 76 
(stromal cells, osteoblasts, osteoclasts, endothelial cells and immune cells) and non-cellular 77 
(ECM) (4, 5). Despite advances in therapies in recent years, MM remains an incurable 78 
disease with a median survival of approximately 5-7 years for newly diagnosed patients (6). 79 
Identification of the molecular mechanisms leading to MM has the potential to lead to the 80 
development of novel prognostic tests and therapies for MM patients (7),(8). 81 
 82 
The extracellular matrix (ECM) is a complex meshwork of proteins that serves as a scaffold 83 
for cells. In addition, it actively participates in cell functions such as proliferation, migration 84 
and survival via cell-to-matrix interactions (9, 10). The ECM is also rich in growth factors 85 
and cytokines thus supporting cell biology (9); therefore it follows that alterations in the 86 
ECM may be expected to occur in disease states such as inflammation and cancer. This is 87 
indeed the case in several tumor types where ECM alterations have been associated with 88 
changes in metastatic potential of tumor cells in vivo and in clinical outcomes (11, 12). The 89 
role of the ECM as a metabolic regulator of cell function also has implications for malignant 90 
processes (13) and molecular signals of metastasis have implicated ECM components and 91 
their receptors in tumor progression (14). In the past, attempts to systematically characterize 92 
the ECM were challenged by the vast diversity and number of ECM proteins and also by 93 
their insolubility and cross-linked nature. A new perspective on analysis of the ECM, on a 94 
relatively high throughput scale, came with the definition and in-vivo characterization of the 95 
“matrisome” (8). The term “matrisome”, initially used by Martin and collaborators in 1984 96 
was updated and refined by Naba et al in 2012. This study revealed tissue specific signatures 97 
of ECM proteins and importantly provided a method to determine the origin (tumor cell or 98 
stroma) of individual matrix proteins.  99 
This, more in-depth knowledge of the ECM composition, was facilitated by whole genome 100 
sequencing. This was made possible due to the fact that ECM proteins are encoded by one or 101 
a few exons in the genome and whole genome sequencing has therefore provided a platform 102 
from which the ECM can be more clearly defined.  Bio-informatic analysis of the proteome, 103 
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using a list of approximately 50 domains to identify a list of candidate ECM proteins, has 104 
facilitated the definition of ECM proteins into a more complete list, which has been named 105 
the “core matrisome’ – in mammals this comprises approximately 300 proteins. These 106 
proteins include large insoluble proteins such as collagens, proteoglycans and glycoproteins 107 
(15). In addition to these insoluble proteins, there are large numbers of ECM-modifying 108 
enzymes, ECM-binding growth factors, and other ECM-associated proteins, which for the 109 
most part are soluble in nature. These proteins have been included in a defined category of  110 
“matrisome-associated” proteins due to the integral role that they play in ECM function (15) . 111 
These different categories of ECM and ECM-associated proteins cooperate to assemble and 112 
remodel the matrix and bind to cells through ECM receptors. Together with receptors for 113 
ECM-bound growth factors, they serve to control survival, proliferation, differentiation, 114 
shape, polarity, and motility of cells (15). 115 
This method of ECM profiling has yielded important insights into the composition of several 116 
solid tumor matrices along with potential novel therapeutic and prognostic targets (11, 16) 117 
however, this method has not been applied to hematological malignancies, where the process 118 
of cell migration from the primary niche is largely dependent on the tumor microenvironment 119 
(17-19).  We characterize the unique extracellular matrices of patients with the pre-myeloma 120 
condition monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed 121 
and relapsed MM patients and compare them to that of healthy human bone marrow. Our 122 
results demonstrate ECM remodeling with disease progression and identify ANXA2 and 123 
LGALS1 as ECM proteins that have prognostic relevance for MM patient overall survival. 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
MATERIALS AND METHODS 135 
 136 
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Human bone marrow aspirates. Informed consent was obtained from all patients in 137 
accordance with the Declaration of Helsinki. These studies were approved by the Dana-138 
Farber Cancer Institute Institutional Review Board and the University of Torino, Italy. Whole 139 
bone marrow (BM) was obtained from healthy human donors (n=10), MGUS patients (n=3), 140 
newly diagnosed MM patients who had not yet received treatment (n=7) and patients with 141 
relapsed MM (n=6). Fresh BM samples (20ml/patient) were filtered and underwent red cell 142 
lysis, followed by centrifugation at 2500rpm for 10 minutes (see Supplementary Methods for 143 
full protocol). The isolated pellet was then processed through the sequential extraction 144 
methods outlined below.  145 
 146 
Murine models and staining for collagen. 147 
Tumors were established in mice using MM1s-GFP-Luc+ cells (5 × 106/ mouse), which were 148 
injected into the tail vein of SCID-Bg mice. Mice were sacrificed at 21 days post injection of 149 
tumor cells, femurs harvested and staining for collagens performed using Masson’s trichrome 150 
stain as a surrogate marker for ECM proteins. 151 
ECM protein enrichment and SDS gradient gel separation. ECM protein enrichment from 152 
of whole BM samples was achieved by sequentially depleting intracellular proteins as 153 
previously described (8, 20). In brief, whole BM samples were homogenized and subjected to 154 
incubations in different buffers to remove (1) cytosolic proteins, (2) nuclear proteins, (3) 155 
membrane proteins and (4) cytoskeletal proteins, leaving a final insoluble fraction enriched 156 
for ECM proteins.  157 
 158 
Immunoblotting. For validation of the extraction process, the different fractions were 159 
separated on SDS-polyacrylamide gradient gels, transferred to nitrocellulose membranes and 160 
probed with relevant subcellular compartmental antibodies to confirm elimination of 161 
intracellular proteins and enrichment of ECM proteins. The antibodies used for 162 
immunoblotting included anti-GAPDH, anti-Histone (Cell Signaling Technology, Danvers, 163 
MA), anti-transferrin (Invitrogen, Camarillo, CA), anti-vimentin (Cell Signaling Technology, 164 
Danvers, MA), anti-fibronectin (Abcam, Cambridge, MA), anti-actin (Santa Cruz 165 
Biotechnology, Dallas, TX) or anti-α-tubulin (Cell Signaling Technology, Danvers, MA).   166 
 167 
Protein digestion in peptides. The ECM-enriched protein fractions obtained after 168 
decellularization were solubilized and reduced in a solution of 8M urea in 100mM 169 
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ammonium bicarbonate containing 10mM dithiotreitol at 37°C for 30 minutes. The 170 
solubilized ECM proteins were then separated on 4-20% SDS-polyacrylamide gradient gels. 171 
Gels were stained with Gel Code Blue (Thermo Scientific) and washed in dH2O. Gels were 172 
then cut into 2 or 3 pieces using a clean scalpel and gel pieces were transferred into clean 173 
microcentrifuge tubes. Gel bands were wash twice with 200mL of 50% acetonitrile for 15 174 
min. Protein gel samples were reduced with 10mM DTT, alkylated with 55mM 175 
iodoacetamide and digested overnight with 100ng of sequencing grade TPCK modified 176 
trypsin (Promega) at pH=8.3. Samples were acidified with 0.5% trifluoroacetic acid and 177 
desalted using C18 zip tips (Millipore) and concentrated to 10uL.  178 
 179 
Liquid chromatography and Tandem Mass Spectrometry. 2 to 4uL of peptides were 180 
analyzed by microcapillary liquid chromatography (C18) tandem mass spectrometry (LC-181 
MS/MS) using an EASY-nLCII nanoflow HPLC (Thermo Fisher Scientific) coupled to a 182 
hybrid Orbitrap Elite high-resolution mass spectrometer (Thermo Fisher Scientific) in Top 6 183 
data-dependent acquisition positive ion mode at a flow rate of 300 nL/min. Please see 184 
supplemental methods for further information. 185 
 186 
Protein and peptide identification. The LC-MS/MS datasets were analyzed with the 187 
Spectrum Mill software package, v 5.0 pre-release (Agilent Technologies, Santa Clara, CA). 188 
MS/MS spectra were searched against UniProt databases containing reference proteome 189 
sequences (including isoforms and excluding fragments) downloaded from the UniProt web 190 
site on October 17, 2014. Redundant sequences were removed, and a set of common 191 
laboratory contaminant proteins (150 sequences) was appended. The human database 192 
comprised 59,079 entries. Search criteria, described in the Supplementary Methods, yielded 193 
target-decoy-based false-discovery rate estimates for each patient’s dataset of <0.8% at the 194 
peptide-spectrum match level and <1.3 % at the distinct peptide level. Across all datasets 195 
together the peptide-level FDR was 1.9%. Peptide-spectrum matches from all datasets 196 
together were assembled into proteins, and each protein was annotated as ECM-derived or 197 
not, as previously described (8, 21). The original mass spectra may be downloaded from 198 
MassIVE (http://massive.ucsd.edu) using the identifier: MSV000080451. The data is directly 199 
accessible via ftp://massive.ucsd.edu/MSV000080451.  200 
 201 
 202 
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Analysis of gene expression profiling and survival analysis. Publicly available gene 203 
expression profiles (GEP) were analyzed to evaluate the expression level of ANXA2 and 204 
LGALS1 in MM patient samples and cell lines (GSE6477)(22). We used the Cancer Cell 205 
Line Encyclopedia (CCLE) database (http://www.broadinstitute.org/ccle/home)(23) to 206 
determine the expression level of ANXA2 and LGALS1 across over 1,000 cell lines, 207 
expressed by Robust Multi-array Average (RMA) values. We further studied GEP to assess 208 
the differential expression of ANXA2 and LGALS1 in MM vs. normal plasma cells – 209 
GSE6477. Gene levels were expressed by normalized expression values and 2-tailed t test 210 
were calculated to compare the 2 groups. Finally, we analyzed a large GEP - GSE2658 (24) – 211 
that enrolled 350 patients at diagnosis of MM. A Kaplan-Meier analysis was performed to 212 
compare overall survival (OS) of patients with low vs. high expression level of ANXA2 or 213 
LGALS1 based on the median expression of the cohort. 214 
 215 
Gene set enrichment analysis (GSEA). We performed gene set enrichment analysis 216 
(GSEA)(25) to determine whether the identified ECM gene sets followed the same pattern at 217 
the mRNA level in MM patients compared to healthy donors. GSEA was performed 218 
following the developer’s protocol (http://www.broad.mit.edu/gsea/) using the GSEA6477 219 
dataset (22). 220 
  221 
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RESULTS 222 
 223 
ECM protein enrichment from normal and diseased whole bone marrow samples. 224 
We have examined murine and human BM, using Masson’s trichrome to stain fibrillar 225 
collagens, as an assessment of ECM content (Fig. 1 and 2). We identified ECM within 226 
healthy murine BM niches and observed that the normal architecture of the ECM became 227 
disorganized in MM murine bone marrow but was still clearly present (Fig. 1A and B). 228 
Similarly, ECM was also identifiable within the BM of MM patients (Fig. 2 A and B), where 229 
morphology most resembled that seen in the MM murine BM. In order to isolate and 230 
characterize this ECM, we developed a protocol based on the previous decellularization 231 
method devised by Naba et al (8) specifically tailored to enrich for insoluble ECM proteins 232 
from the liquid marrow (Fig. 3A). Antibody markers, including anti-GAPDH, -histone, -233 
transferrin receptor, and –vimentin were used for the cytosolic, nuclear, membrane and 234 
cytoskeletal compartments in order to confirm depletion of intracellular components at each 235 
step (Fig. 3B, left panel). In addition, we used an anti-fibronectin antibody to monitor the 236 
behavior of one exemplary ECM protein during the decellularization of bone marrow 237 
samples. Although we observed a portion of fibronectin to be partially depleted at each step, 238 
it was present in the final fraction (Fig. 3B, left panel). The protein fraction that remains 239 
insoluble after decellularization was then separated using gel electrophoresis, gels were 240 
stained using Coomassie blue stain (Fig. 3B, right panel). Gel bands were further cut from the 241 
gels and proteins were subjected to in-gel protein digestion to generate peptides to be 242 
separated by liquid chromatography and analyzed by mass spectrometry.  243 
 244 
Proteomic characterization of healthy human donor, MGUS and MM ECM.  245 
We aimed to define the proteomic signature of BM ECMs obtained from patients with 246 
MGUS and MM, as compared to healthy donors-derived BM ECMs. Complete data acquired 247 
on independent samples from healthy donors, MGUS patients and MM patients is shown in 248 
Supplementary Table S3. Peptide abundance, spectral count, number of unique peptides and 249 
number of proteins identified within the whole bone marrow were measured for both healthy 250 
donors and patients with MGUS or MM, either at first diagnosis or at relapse (Supplementary 251 
Fig. S1). In a representative healthy donor-derived sample, 24% of total spectral count 252 
signals were core matrisome or matrisome associated with 43% of the total precursor-ion 253 
intensity corresponding to proteins defined as ECM (Fig. S1A). A similar pattern was 254 
demonstrated for MGUS, newly diagnosed and relapsed MM BM ECMs (Fig. S1B-D. and 255 
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Supplementary Table S3B-E). In previous studies conducted on solid tumors (melanoma or 256 
mammary tumor xenografts, and human metastatic colorectal carcinomas), we have reported 257 
that the majority, typically (>75%) of the total precursor-ion intensities, correspond to 258 
matrisome proteins (8, 11, 16). This may indicate that the bone marrow ECM is comprised of 259 
a larger fraction of soluble ECM components, which by their nature are more readily 260 
extractable during the decellularization process than the ECM of normal tissues and solid 261 
tumors, where the ECM may play a greater structural role, and therefore be higher in in-262 
soluble components. In addition, it is worth noting that the inter-patient variability was 263 
greater than what we previously observed in solid tumor 11. Starting with 20 ml of bone 264 
marrow aspirate for each donor or patient, we observed that the proportion of the total 265 
precursor-ion intensities corresponding to matrisome proteins ranged from 10% to nearly 266 
50%, (see Supplementary Fig. S2 and Supplementary Table S3A).  267 
 268 
Characterization of the matrisome from healthy donor bone marrow. 269 
We defined the matrisome of healthy-donor-derived BM as the ensemble of proteins detected 270 
in at least three independent biological replicates (i.e. patients) and by at least three peptides 271 
in one of the replicates. According to this definition the BM ECM from 10 independent 272 
healthy donors was composed of 62 proteins (Supplementary Table S1A). We previously 273 
proposed to classify proteins as part of the core matrisome, which comprises ECM 274 
glycoproteins, collagens, and proteoglycans, or being matrisome-associated proteins (ECM-275 
affiliated proteins, ECM regulators, and ECM-associated secreted factors) (8, 21). The human 276 
bone marrow matrisome comprises 30 core matrisome proteins and 32 matrisome-associated 277 
proteins (Supplementary Table S1A, Supplementary Table S3B). The interrogation of the 278 
MatrisomeDB database (21) further revealed the identification of 11 proteins that have not 279 
been previously detected in any of the human tissues included in the database 280 
(Supplementary Table S1A). As human BM has not been previously subjected to this type of 281 
method, these proteins may be specific to this tissue.  282 
 283 
Characterization of the matrisome from MGUS and MM patients.  284 
We next sought to define the proteomic signature for BM ECMs derived from MGUS 285 
patients, using the same criteria outlined above, and found 11 proteins, two of which were 286 
core matrisome proteins, namely Bone Marrow Proteoglycan 2 (PRG2) and Bone Marrow 287 
proteoglycan 3 (PRG3) (Supplementary Table S1B). Nine of the proteins identified in the 288 
MGUS patient bone marrows were matrisome associated, including the ECM-affiliated 289 
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protein ficolin 1 (FCN1), the ECM-remodeling enzymes CTSG, Serpins, and the secreted 290 
factors HRNR, S100A8 and S100A9 (Supplementary Table S1B).  291 
Analysis of the ECM signature of MM bone marrow identified 32 proteins (Supplementary 292 
Table S1C). Ten of these proteins were core matrisome proteins, with 22 being matrisome 293 
associated. Interestingly two matrisome associated proteins were identified, Annexin A2 294 
(ANXA2) and Galectin-1 (LGALS1), which were not identified in healthy donor or MGUS 295 
bone marrow. The ECM of patients with relapsed MM comprised of 25 proteins, 10 of which 296 
are core matrisome proteins and 15 of which are matrisome associated (Supplementary Table 297 
S1D).  298 
 299 
The analysis of the ECM identified signatures of MGUS and progressive MM.  300 
By comparing the matrisomes of healthy donor bone marrow, MGUS and progressive stages 301 
of MM, we identified 11 proteins expressed by all four groups (Fig. 4A-B). Examples of 302 
these proteins are cathepsin-G (CTSG) and neutrophil elastase (ELANE). We further 303 
remarked that the normal-bone-marrow matrisome contained more proteins than diseased 304 
bone marrow samples. Because the proteomic pipeline employed analyzed only proteins that 305 
remained insoluble after decellularization, one hypothesis is that the ECM proteins in MGUS 306 
or MM bone marrow samples are more soluble. In agreement with this hypothesis, we 307 
observed the loss of several collagens and other fibrillar ECM glycoproteins such as 308 
fibronectin in MGUS and MM samples (Supplementary Table S2, Supplementary Table 309 
S3B-E). We also observed that some collagens and matrix metallo-proteinases (MMPs) 310 
found in healthy donor bone marrow and not detected at the MGUS stage are detected later in 311 
the disease progression pathway.  This includes, among others, COL1A1, COL1A2, 312 
COL3A1, COL5A1, MMP8 and MMP9 (Supplementary Table S2). When comparing newly 313 
diagnosed MM to healthy donor BM and that of MGUS, Interestingly, two proteins, Annexin 314 
A2 and Galectin-1 are seen to emerge that are not present in earlier stages of the disease (Fig. 315 
4B, Supplementary Table S2).  316 
 317 
MM cells present with an enrichment for ECM-related genes.  318 
We further validated the findings at the proteomic level by performing an analysis of the 319 
corresponding mRNA gene expression in MM plasma cells. 320 
Using the signature of ECM proteins found to be present in the normal ECM, and absent in 321 
the MM tumor ECM, we performed GSEA to assess for enrichment of this gene signature in 322 
healthy donors vs. MM patients. Enrichment of the corresponding ECM gene signature was 323 
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demonstrated in healthy donors compared to MM patients (Fig. 5A-B; FDR<0.25). It has 324 
been shown that the majority of the tumor ECM is derived from the tumor cells in the main 325 
part, with stromal contribution at different stages of metastasis (16).  Our findings of an 326 
altered ECM signature suggest that plasma cells may co-ordinate ECM remodeling in this 327 
disease. The interaction between the altered ECM and other bone marrow micro-328 
environmental elements is likely to further augment the bone marrow milieu, creating a 329 
permissive environment for MM progression.  330 
 331 
Annexin A2 and Galectin-1 and their prognostic relevance in MM. 332 
ANXA2 and LGALS1, two ECM-affiliated proteins, were identified in newly diagnosed MM 333 
BM-ECMs, and not in healthy donor or MGUS BM-ECMs. We therefore analyzed the 334 
expression of ANXA2 and LGALS1 in MM cell lines, using the Cancer Cell Line 335 
Encyclopedia (CCLE); and found that both proteins were expressed in all MM cell lines (Fig. 336 
6A and 7A). These observations were further corroborated by demonstrating the higher 337 
expression of both ANXA2 and LGALS1 in BM MM- as compared to healthy donor-derived 338 
plasma cells (GSE2658 and GSE6477; Fig. 6B and 7B) (22) (26).  339 
Specifically, while ANXA2 levels were consistently higher in any given MGUS, smoldering-340 
MM, MM newly diagnosed or MM relapsed patient as compared to healthy donors, LGALS1 341 
was significantly higher in MGUS and newly diagnosed MM patients as compared to healthy 342 
individuals (Fig. 7B). 343 
In order to further understand if these targets may be leading to a permissive tumor 344 
microenvironment in MM, we analyzed the Mulligan dataset (27) for co-expression of these 345 
genes in MM using the publically available Oncomine resource (www.oncomine.org); we 346 
found that ANXA2 is one of the most highly co-expressed genes with LGALS1 in 264 MM 347 
patients (Fig. 8A; correlation coefficient = 0.522).  348 
We next interrogated the influence of both ANXA2 and LGALS1 in modulating survival in 349 
MM patients. By examining GSE2658 (28), and found that patients expressing higher levels 350 
of ANXA2 had a significantly reduced overall survival (OS) compared with those with lower 351 
expression levels (Fig. 8B; Log-rank p=4.9e-05). Similarly, high levels of LGALS1 were also 352 
associated with an inferior OS (Fig. 8C Log-rank P = 0.05)  353 
DISCUSSION  354 
 355 
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In this study, we report the profiling of the ECM composition of normal bone marrow using 356 
mass spectrometry. We have compared this profile to the composition of the ECM of patients 357 
with MGUS, newly diagnosed, and relapsed multiple myeloma.  358 
Our results demonstrate that significant remodeling of the bone marrow ECM is evident even 359 
at the MGUS stage, with loss of collagens and fibronectin (COL4A1-A3, COL4A6, 360 
COL5A2-3, COL6A2-3 COL10A1, COL11A2, COL16A1, COL27A1 and FN1). The 361 
absence of these proteins was consistent throughout the spectrum of MM from newly 362 
diagnosed to relapsed disease suggesting that the loss of these ECM components may 363 
contribute to a permissive tumor microenvironment supportive of the development and 364 
progression of MM. Indeed it has been shown that fibroblasts from patients with MGUS and 365 
MM demonstrate altered ECM profiles in comparison to those of healthy donors, supporting 366 
the hypothesis of early ECM remodeling (29).  367 
Similarly, some collagens and matrix metallo-proteinases found in healthy donor bone 368 
marrow are not detected at the MGUS stage but are seen to re-emerge in the disease 369 
progression pathway indicating that they may be more supportive in aggressive phenotypes. 370 
This includes, among others, COL1A1, COL1A2, COL3A1, COL5A1, MMP8 and MMP9. 371 
Interestingly, two proteins, Annexin A2 (ANXA2) and Galectin-1 (LGALS1) were detected 372 
in newly diagnosed MM but not in healthy donors or MGUS patients. These proteins were 373 
confirmed as being expressed in MM cell lines at the mRNA level in CCLE datasets. We 374 
hypothesized that these proteins may be required for myelomagenesis and further examined 375 
their presence in MM patient bone marrow.  376 
Our analysis of GEP profiles reveals that these proteins are highly expressed in MM bone 377 
marrow plasma cells in comparison to healthy-donor-derived plasma cells. This may indicate 378 
that these proteins are produced by the tumor cells within the bone marrow niche and are 379 
specific to the malignant phenotype. If this is the case, then plasma cells themselves may 380 
contribute to bone marrow ECM remodeling as has been shown in other tumors (16). This 381 
may occur as a result of interactions between the remodeled ECM and other micro-382 
environmental elements as altered ECMs in cancer deregulate the behavior of stromal cells, 383 
facilitate angiogenesis and promote a tumorigenic micro-environment (30). Altered ECM 384 
composition and topography indirectly affects cancer cells by influencing the effect of 385 
stromal cells, immune cells and fibroblasts which alters the tumor niche, this is also likely to 386 
be the case in multiple myeloma given our findings, however further work is needed to 387 
confirm this (30-32). Indeed, the galectins, of which LGALS1 is a member, are a family of 388 
beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix 389 
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interactions and recently Galectin-1 suppression has been shown to inhibit MM induced 390 
angiogenesis and tumor growth in-vivo (33). Annexin A2 is a calcium dependent 391 
phospholipid binding protein, which plays a role in cell growth and heightens osteoclast 392 
formation and bone resorption. Osteoclasts are known to contribute to an immune 393 
suppressive microenvironment in MM and are widely known to be associated with MM 394 
pathogenesis (34). Also, ANXA2 has previously been shown to promote MM cell growth and 395 
reduce apoptosis in MM cell lines (35). Identification of these targets, known to play a role in 396 
MM biology, helps to provide a wider validation of the remodeling of the ECM signature 397 
emerging using this novel strategy.  398 
To further understand the implications of bone marrow remodeling in MM patients, we 399 
examined if there might be a common expression pattern for these two proteins within the 400 
MM bone marrow niche. Using data from Oncomine, we analyzed 264 MM patients and 401 
found that ANXA2 is one of the most highly co-expressed genes with LGALS1 in these 402 
patients. This leads us to hypothesize that the bone marrow remodeling seen in MM is likely 403 
to be an organized process that occurs as a result of multiple ECM protein switches being 404 
turned on and off within the bone marrow niche. Although both of these markers have 405 
previously been identified as being important in MM, we have further validated them as 406 
being part of an overall ECM remodeling process within the bone marrow.  407 
The prognostic relevance of our findings was determined using GEP datasets, which provided 408 
survival outcomes for MM patients. This demonstrated that patients expressing higher levels 409 
of ANXA2 had a significantly reduced overall survival compared with those with lower 410 
expression levels. Similarly, high levels of LGALS1 were also associated with a shorter 411 
overall survival. This finding demonstrates that the bone marrow ECM plays an important 412 
role in MM and suggests that ECM remodeling is an active process within the bone marrow 413 
niche that has prognostic implications for MM patients. We can postulate that with the 414 
development of i) technologies to characterize the proteome and the matrisome with greater 415 
depth (including orthogonal peptide separation) and ii) methods to conduct quantitative 416 
analyses, we will be able to identify many more proteins, some of which may have prognostic 417 
values for MM patients. This previously under-evaluated area provides a potential resource 418 
for the identification of novel targets in this disease which may lead the way to preserving the 419 
normal ECM architecture and a less permissive niche.  420 
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FIGURE LEGENDS 534 
 535 
Figure 1. Staining of fibrillar collagens using Masson's trichrome (blue) of  mouse bone 536 
marrow samples.  537 
A. Healthy murine bone marrow. 538 
B. Multiple myeloma murine bone marrow. 539 
 540 
Figure 2. Staining of fibrillar collagens using Masson's trichrome (blue) of human bone 541 
marrow samples.  542 
A. Healthy human bone marrow. 543 
B. Multiple myeloma human bone marrow. 544 
 545 
Figure 3. Proteomic pipeline to characterize the ECM compoistion of normal and 546 
diseased bone marrow samples. 547 
A. Experimental pipeline. 548 
B. Western blot to control the efficiency of the decellularization of bone marrow samples. 549 
Western blot shows the depletion of intracellular components (GAPDH, histones, Transferrin 550 
receptor and vimentin) during the four-step decellularization process.  551 
Coomassie-stained gel shows the pattern of migration of proteins from the ECM-enriched 552 
samples. 553 
 554 
Figure 4. Comparison of the matrisome of normal and diseased bone marrow samples. 555 
A. Bar chart represents the number of proteins constituting the matrisome of normal, MGUS, 556 
newly diagnosed MM, and relapsed MM bone marrow. 557 
B. Venn diagram illustrated the overlap between the matrisome proteins detected in normal, 558 
MGUS, newly diagnosed MM, and relapsed MM bone marrow (Supplementary Table S2). 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
Figure 5. Gene set enrichment analysis of matrisome gene signature in MM patients. 567 
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A. Gene set enrichment analysis (GSEA): demonstrating that (A) ECM proteins seen to be 568 
depleted in the bone marrow matrix with disease progression were also significantly down 569 
regulated at the gene level in normal donors (left) compared to MM patients (right). 570 
B. Heatmap demonstrating enrichment profile of relevant ECM genes in healthy donors vs. 571 
MM patients.  572 
Figure 6: Gene expression of ANXA2 in MM cell lines. 573 
A. Analysis of CCLE MM cell lines (red bars) demonstrating the expression ANXA2 in MM 574 
cell lines at the mRNA level.  575 
B. ANXA2 is significantly overexpressed at the mRNA level in MGUS, smoldering MM 576 
(SMM), newly diagnosed MM (MM, ndx) and relapsed MM (MM relapse) in comparison to 577 
normal donors (ND). Dataset reference: Cancer Res. 2007 Apr 1;67(7):2982-9. (GSE6477) 578 
 579 
Figure 7: Gene expression of LGALS1 in MM cell lines. 580 
A. LGALS1 is also significantly overexpressed at the mRNA level in newly diagnosed MM 581 
patients compared to normal donors in CCLE dataset.   582 
B. LGALS1 is significantly overexpressed at the mRNA level in MGUS, smoldering MM 583 
(SMM), newly diagnosed MM (MM, ndx) and relapsed MM (MM relapse) in comparison to 584 
normal donors (ND). Dataset reference: Cancer Res. 2007 Apr 1;67(7):2982-9. (GSE6477) 585 
 586 
Figure 8. Expression of ECM proteins in MM patients and impact on overall survival. 587 
A. Co-expression of LGALS1 and ANXA2 in MM patients – data sourced from Oncomine 588 
(www.oncomine.org) Mulligan MM gene expression Blood. 2007 Apr 15;109(8):3177-88. 589 
Epub 2006 Dec 21. 590 
B. Kaplan-Meier survival proportions analysis of patient outcome data from the GSE2658 591 
MM GEP dataset demonstrating high levels of ANXA2 expression associated with inferior 592 
overall survival. Log-rank P = 4.9e-05 593 
C. Kaplan-Meier survival proportions analysis of patient outcome data from the GSE2658 594 
MM GEP dataset demonstrating high levels of LGALS1 expression associated with inferior 595 
overall survival. Log-rank P = 0.051. 596 
  597 
 598 
 599 
Supplementary Table S1. Bone marrow matrisome. Matrisome of the bone marrow from 600 
healthy donors (A), MGUS patients (B), newly diagnosed multiple myeloma patients (C), and 601 
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relapsed multiple myeloma patients (D). * indicates ECM or ECM-associated proteins not 602 
detected before in any human tissue matrisome. 603 
 604 
Supplementary Table S2. Comparison of the matrisome of normal, MGUS, newly 605 
diagnosed MM, and relapsed MM bone marrow 606 
Supplementary Table S3.  Proteomic data 607 
A.  Complete proteomic dataset. Proteins are sorted by matrisome categories and then by 608 
Entrez Gene Symbol. 609 
B-E. The total precursor-ion intensity, number of spectra and unique peptides were calculated 610 
for each protein and in each sample. Proteins are sorted by number of observations (column 611 
D), then matrisome categories (column B) and gene symbols (column C). Proteins detected in 612 
at least 3 patients and with at least 3 peptides in one of the samples compose the matrisome 613 
of each of the four bone marrow sample types (bold). 614 
B. All ECM and ECM-associated proteins detected in normal bone marrow samples.  615 
C. All ECM and ECM-associated proteins detected in bone marrow samples from MGUS 616 
samples.  617 
D. All ECM and ECM-associated proteins detected in bone marrow samples from newly 618 
diagnosed multiple myeloma patients.  619 
E. All ECM and ECM-associated proteins detected in bone marrow samples from relapsed 620 
multiple myeloma patients.  621 
F. Name of raw mass spectrometry files.  622 
 623 
Supplementary Figure 1: Proteomic metrics.  624 
Pie charts represent relative amount of core matrisome (blue), matrisome-associated (orange) 625 
and other (grey) proteins in terms of peptide abundance, and numbers of spectra, unique 626 
peptides and proteins. 627 
A. Metrics for representative normal bone marrow sample. 628 
B. Metrics for representative MGUS sample. 629 
C. Metrics for representative newly diagnosed multiple myeloma sample. 630 
D. Metrics for representative relapsed multiple myeloma sample. 631 
 632 
Supplementary Figure 2: ECM peptide abundance 633 
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Bar charts represent the peptide abundance for ECM vs non-ECM proteins (A) and for core 634 
matrisome and matrisome-associated proteins (B) in each sample analyzed. 635 
 636 
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ABSTRACT 
 
The extracellular matrix (ECM) is a major component of the tumor microenvironment, 
contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In 
multiple myeloma (MM), interactions between MM cells and the bone marrow (BM) 
microenvironment, including the BM ECM, are critical to the pathogenesis of the disease and 
the development of drug resistance. Nevertheless, composition of the ECM in MM and its 
role in supporting MM pathogenesis has not been reported. We have applied a novel 
proteomic-based strategy and defined the BM ECM composition in patients with monoclonal 
gammopathy of undetermined significance (MGUS), newly diagnosed and relapsed MM 
compared to healthy donor-derived BM ECM. In this study, we show that the tumor ECM is 
remodeled at the mRNA and protein level in MGUS and MM to allow development of a 
permissive microenvironment. We further demonstrate that two ECM-affiliated proteins, 
ANXA2 and LGALS1, are more abundant in MM and high expression is associated with a 
decreased overall survival. This study points to the importance of ECM remodeling in MM 
and provides a novel proteomic pipeline for interrogating the role of the ECM in cancers with 
BM tropism. 
 
Keywords: Multiple Myeloma, Extracellular Matrix, Proteomics 
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INTRODUCTION 
 
Multiple myeloma (MM) is a plasma cell malignancy and accounts for approximately 10% of 
all hematological cancers (1). MM provides a model for the study of cancer cell metastasis as 
MM cells are known to traffic to distant bone marrow (BM) niches via hijacking the normal 
processes of cellular metastasis (2). Progression of the disease is mediated by intrinsic factors 
of the clonal cells along with factors that mediate a permissive tumor microenvironment (3). 
The MM tumor niche comprises the components of the BM microenvironment - cellular 
(stromal cells, osteoblasts, osteoclasts, endothelial cells and immune cells) and non-cellular 
(ECM) (4, 5). Despite advances in therapies in recent years, MM remains an incurable 
disease with a median survival of approximately 5-7 years for newly diagnosed patients (6). 
Identification of the molecular mechanisms leading to MM has the potential to lead to the 
development of novel prognostic tests and therapies for MM patients (7),(8). 
 
The extracellular matrix (ECM) is a complex meshwork of proteins that serves as a scaffold 
for cells. In addition, it actively participates in cell functions such as proliferation, migration 
and survival via cell-to-matrix interactions (9, 10). The ECM is also rich in growth factors 
and cytokines thus supporting cell biology (9); therefore it follows that alterations in the 
ECM may be expected to occur in disease states such as inflammation and cancer. This is 
indeed the case in several tumor types where ECM alterations have been associated with 
changes in metastatic potential of tumor cells in vivo and in clinical outcomes (11, 12). The 
role of the ECM as a metabolic regulator of cell function also has implications for malignant 
processes (13) and molecular signals of metastasis have implicated ECM components and 
their receptors in tumor progression (14). In the past, attempts to systematically characterize 
the ECM were challenged by the vast diversity and number of ECM proteins and also by 
their biochemical nature. A new perspective on analysis of the ECM, on a relatively high 
throughput scale, came with the definition and in-vivo characterization of the “matrisome” 
(8). The term “matrisome”, initially used by Martin and collaborators in 1984 was updated 
and refined by Naba et al in 2012. This study revealed tissue specific signatures of ECM 
proteins and importantly provided a method to determine the origin (tumor cell or stroma) of 
individual matrix proteins. The “matrisome” itself is defined as the components constituting 
the ECM “core matrisome” and all associated components “matrisome associated”. This 
method has yielded important insights into the composition of several solid tumor matrices 
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along with potential novel therapeutic and prognostic targets (11, 15). ECM alterations that 
influence cellular metastasis have implications not only for solid tumors but also for 
hematological malignancies, where the process of cell migration from the primary niche is 
largely dependent on the tumor microenvironment (16-18).   
In this study we apply a mass-spectrometry-based proteomic pipeline to study the tumor 
ECM from the bone marrow of MM patients. We characterize the unique extracellular 
matrices of patients with the pre-myeloma condition monoclonal gammopathy of 
undetermined significance (MGUS), newly diagnosed and relapsed MM patients and 
compare these ECM signatures to that of healthy human donor bone marrow. Our results 
demonstrate ECM remodeling with disease progression, as early at the MGUS stage. We 
further identify ANXA2 and LGALS1, two ECM-associated proteins as markers of the MM 
ECM and show the prognostic value of their expression for multiple-myeloma-patient overall 
survival. 
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MATERIALS AND METHODS 
 
Human bone marrow aspirates. Informed consent was obtained from all patients in 
accordance with the Declaration of Helsinki. These studies were approved by the Dana-
Farber Cancer Institute Institutional Review Board and the University of Torino, Italy. Whole 
bone marrow (BM) was obtained from healthy human donors (n=10), MGUS patients (n=3), 
newly diagnosed MM patients who had not yet received treatment (n=7) and patients with 
relapsed MM (n=6). Fresh BM samples (20ml/patient) were filtered and underwent red cell 
lysis, followed by centrifugation at 2500rpm for 10 minutes (see Supplementary Methods for 
full protocol). The isolated pellet was then processed through the sequential extraction 
methods outlined below.  
 
ECM protein enrichment and SDS gradient gel separation. ECM protein enrichment from 
of whole BM samples was achieved by sequentially depleting intracellular proteins as 
previously described (8, 19). In brief, whole BM samples were homogenized and subjected to 
incubations in different buffers to remove (1) cytosolic proteins, (2) nuclear proteins, (3) 
membrane proteins and (4) cytoskeletal proteins, leaving a final insoluble fraction enriched 
for ECM proteins.  
 
Immunoblotting. For validation of the extraction process, the different fractions were 
separated on SDS-polyacrylamide gradient gels, transferred to nitrocellulose membranes and 
probed with relevant subcellular compartmental antibodies to confirm elimination of 
intracellular proteins and enrichment of ECM proteins. The antibodies used for 
immunoblotting included anti-GAPDH, anti-Histone (Cell Signaling Technology, Danvers, 
MA), anti-transferrin (Invitrogen, Camarillo, CA), anti-vimentin (Cell Signaling Technology, 
Danvers, MA), anti-fibronectin (Abcam, Cambridge, MA), anti-actin (Santa Cruz 
Biotechnology, Dallas, TX) or anti-α-tubulin (Cell Signaling Technology, Danvers, MA).   
 
Protein digestion in peptides. The ECM-enriched protein fractions obtained after 
decellularization were solubilized and reduced in a solution of 8M urea in 100mM 
ammonium bicarbonate containing 10mM dithiotreitol at 37°C for 30 minutes. The 
solubilized ECM proteins were then separated on 4-20% SDS-polyacrylamide gradient gels. 
Gels were stained with Gel Code Blue (Thermo Scientific) and washed in dH2O. Gels were 
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then cut into 2 or 3 pieces using a clean scalpel and gel pieces were transferred into clean 
microcentrifuge tubes. Gel bands were wash twice with 200mL of 50% acetonitrile for 15 
min. Protein gel samples were reduced with 10mM DTT, alkylated with 55mM 
iodoacetamide and digested overnight with 100ng of sequencing grade TPCK modified 
trypsin (Promega) at pH=8.3. Samples were acidified with 0.5% trifluoroacetic acid and 
desalted using C18 zip tips (Millipore) and concentrated to 10uL.  
 
Liquid chromatography and Tandem Mass Spectrometry. 2 to 4uL of peptides were 
analyzed by microcapillary liquid chromatography (C18) tandem mass spectrometry (LC-
MS/MS) using an EASY-nLCII nanoflow HPLC (Thermo Fisher Scientific) coupled to a 
hybrid Orbitrap Elite high-resolution mass spectrometer (Thermo Fisher Scientific) in Top 6 
data-dependent acquisition positive ion mode at a flow rate of 300 nL/min.  
 
Protein and peptide identification. The LC-MS/MS datasets were analyzed with the 
Spectrum Mill software package, v 5.0 pre-release (Agilent Technologies, Santa Clara, CA). 
MS/MS spectra were searched against UniProt databases containing reference proteome 
sequences (including isoforms and excluding fragments) downloaded from the UniProt web 
site on October 17, 2014. Redundant sequences were removed, and a set of common 
laboratory contaminant proteins (150 sequences) was appended. The human database 
comprised 59,079 entries. Search criteria, described in the Supplementary Methods, yielded 
target-decoy-based false-discovery rate estimates for each patient’s dataset of <0.8% at the 
peptide-spectrum match level and <1.3 % at the distinct peptide level. Across all datasets 
together the peptide-level FDR was 1.9%. Peptide-spectrum matches from all datasets 
together were assembled into proteins, and each protein was annotated as ECM-derived or 
not, as previously described (8, 20).  
The raw mass spectrometric data have been deposited to the ProteomeXchange Consortium.  
 
Analysis of gene expression profiling and survival analysis. Publicly available gene 
expression profiles (GEP) were analyzed to evaluate the expression level of ANXA2 and 
LGALS1 in MM patient samples and cell lines (GSE6477)(21). We used the Cancer Cell 
Line Encyclopedia (CCLE) database (http://www.broadinstitute.org/ccle/home)(22) to 
determine the expression level of ANXA2 and LGALS1 across over 1,000 cell lines, 
expressed by Robust Multi-array Average (RMA) values. We further studied GEP to assess 
the differential expression of ANXA2 and LGALS1 in MM vs. normal plasma cells – 
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GSE6477. Gene levels were expressed by normalized expression values and 2-tailed t test 
were calculated to compare the 2 groups. Finally, we analyzed a large GEP - GSE2658 (23) – 
that enrolled 350 patients at diagnosis of MM. A Kaplan-Meier analysis was performed to 
compare overall survival (OS) of patients with low vs. high expression level of ANXA2 or 
LGALS1 based on the median expression of the cohort. 
 
Gene set enrichment analysis (GSEA). We performed gene set enrichment analysis 
(GSEA)(24) to determine whether the identified ECM gene sets followed the same pattern at 
the mRNA level in MM patients compared to healthy donors. GSEA was performed 
following the developer’s protocol (http://www.broad.mit.edu/gsea/) using the GSEA6477 
dataset (21). 
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RESULTS 
 
ECM protein enrichment from normal and diseased whole bone marrow samples. 
We have examined murine and human BM, using Masson’s trichrome to stain fibrillar 
collagens, as an assessment of ECM content (Fig. 1 and 2). We identified ECM within 
healthy murine BM niches and observed that the normal architecture of the ECM became 
disorganized in MM murine bone marrow but was still clearly present (Fig. 1A and B). 
Similarly, ECM was also identifiable within the BM of MM patients (Fig. 2 A and B), where 
morphology most resembled that seen in the MM murine BM. In order to isolate and 
characterize this ECM, we developed a protocol based on the previous decellularization 
method devised by Naba et al (8) specifically tailored to enrich for insoluble ECM proteins 
from the liquid marrow (Fig. 3A). Antibody markers, including anti-GAPDH, -histone, -
transferrin receptor, and –vimentin were used for the cytosolic, nuclear, membrane and 
cytoskeletal compartments in order to confirm depletion of intracellular components at each 
step (Fig. 3B, left panel). In addition, we used an anti-fibronectin antibody to monitor the 
behavior of one exemplary ECM protein during the decellularization of bone marrow 
samples. Although we observed a portion of fibronectin to be partially depleted at each step, 
it was present in the final fraction (Fig. 3B, left panel). The protein fraction that remains 
insoluble after decellularization was then separated using gel electrophoresis, gels were 
stained using Coomassie blue stain (Fig. 3B, right panel). Gel bands were further cut from the 
gels and proteins were subjected to in-gel protein digestion to generate peptides to be 
separated by liquid chromatography and analyzed by mass spectrometry.  
 
Proteomic characterization of healthy human donor, MGUS and MM ECM.  
We aimed to define the proteomic signature of BM ECMs obtained from patients with 
MGUS and MM, as compared to healthy donors-derived BM ECMs. Complete data acquired 
on independent samples from healthy donors, MGUS patients and MM patients is shown in 
Supplementary Table S3. Peptide abundance, spectral count, number of unique peptides and 
number of proteins identified within the whole bone marrow were measured for both healthy 
donors and patients with MGUS or MM, either at first diagnosis or at relapse (Supplementary 
Fig. S1). In a representative healthy donor-derived sample, 24% of total spectral count 
signals were core matrisome or matrisome associated with 43% of the total precursor-ion 
intensity corresponding to proteins defined as ECM (Fig. S1A). A similar pattern was 
demonstrated for MGUS, newly diagnosed and relapsed MM BM ECMs (Fig. S1B-D. and 
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Supplementary Table S3B-E). In previous studies conducted on solid tumors (melanoma or 
mammary tumor xenografts, and human metastatic colorectal carcinomas), we have reported 
that the majority, typically (>75%) of the total precursor-ion intensities, correspond to 
matrisome proteins (8, 11, 15). This may reveal that the bone marrow ECM is more soluble 
and more readily extractable during the decellularization process than the ECM of normal 
tissues and solid tumors. In addition, it is worth noting that the inter-patient variability was 
greater than what we previously observed in solid tumor 11. Starting with 20 ml of bone 
marrow aspirate for each donor or patient, we observed that the proportion of the total 
precursor-ion intensities corresponding to matrisome proteins ranged from 10% to nearly 
50%, (see Supplementary Fig. S2 and Supplementary Table S3A).  
 
Characterization of the matrisome from healthy donor bone marrow. 
We defined the matrisome of healthy-donor-derived BM as the ensemble of proteins detected 
in at least three independent biological replicates (i.e. patients) and by at least three peptides 
in one of the replicates. According to this definition the BM ECM from 10 independent 
healthy donors was composed of 62 proteins (Supplementary Table S1A). We previously 
proposed to classify proteins as part of the core matrisome, which comprises ECM 
glycoproteins, collagens, and proteoglycans, or being matrisome-associated proteins (ECM-
affiliated proteins, ECM regulators, and ECM-associated secreted factors) (8, 20). The human 
bone marrow matrisome comprises 30 core matrisome proteins and 32 matrisome-associated 
proteins (Supplementary Table S1A, Supplementary Table S3B). The interrogation of the 
MatrisomeDB database (20) further revealed the identification of 11 proteins that have not 
been previously detected in any of the human tissues included in the database 
(Supplementary Table S1A). As human BM has not been previously subjected to this type of 
method, these proteins may be specific to this tissue.  
 
Characterization of the matrisome from MGUS and MM patients.  
We next sought to define the proteomic signature for BM ECMs derived from MGUS 
patients, using the same criteria outlined above, and found 11 proteins, two of which were 
core matrisome proteins, namely Bone Marrow Proteoglycan 2 (PRG2) and Bone Marrow 
proteoglycan 3 (PRG3) (Supplementary Table S1B). Nine of the proteins identified in the 
MGUS patient bone marrows were matrisome associated, including the ECM-affiliated 
protein ficolin 1 (FCN1), the ECM-remodeling enzymes CTSG, Serpins, and the secreted 
factors HRNR, S100A8 and S100A9 (Supplementary Table S1B).  
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Analysis of the ECM signature of MM bone marrow identified 32 proteins (Supplementary 
Table S1C). Ten of these proteins were core matrisome proteins, with 22 being matrisome 
associated. Interestingly two proteins were identified as matrisome associated, Annexin A2 
(ANXA2) and Galectin-1 (LGALS1), which were not identified at a significant level in 
healthy donor or MGUS bone marrow. The ECM of patients with relapsed MM comprised of 
25 proteins, 10 of which are core matrisome proteins and 15 of which are matrisome 
associated (Supplementary Table S1D).  
 
The analysis of the ECM identified signatures of MGUS and progressive MM.  
By comparing the matrisomes of healthy donor bone marrow, MGUS and progressive stages 
of MM, we identified 11 proteins expressed by all four groups (Fig. 4A-B). Examples of 
these proteins are cathepsin-G (CTSG) and neutrophil elastase (ELANE). We further 
remarked that the normal-bone-marrow matrisome contained more proteins than diseased 
bone marrow samples. Because the proteomic pipeline employed analyzed only proteins that 
remained insoluble after decellularization, one hypothesis is that the ECM proteins in MGUS 
or MM bone marrow samples are more soluble. In agreement with this hypothesis, we 
observed the loss of several collagens and other fibrillar ECM glycoproteins such as 
fibronectin in MGUS and MM samples (Supplementary Table S2, Supplementary Table 
S3B-E). We also observed that some collagens and matrix metallo-proteinases (MMPs) 
found in healthy donor bone marrow and not detected at the MGUS stage are detected later in 
the disease progression pathway.  This includes, among others, COL1A1, COL1A2, 
COL3A1, COL5A1, MMP8 and MMP9 (Supplementary Table S2). When comparing newly 
diagnosed MM to healthy donor BM and that of MGUS, Interestingly, two proteins, Annexin 
A2 and Galectin-1 are seen to emerge that are not present in earlier stages of the disease (Fig. 
4B, Supplementary Table S2).  
 
MM cells present with an enrichment for ECM-related genes.  
We further validated the findings at the proteomic level by performing an analysis of the 
corresponding mRNA gene expression in MM plasma cells. 
Using the signature of ECM proteins found to be present in the normal ECM, and absent in 
the MM tumor ECM, we performed GSEA to assess for enrichment of this gene signature in 
healthy donors vs. MM patients. Enrichment of the corresponding ECM gene signature was 
demonstrated in healthy donors compared to MM patients (Fig. 5A-B; FDR<0.25). It has 
been shown that the majority of the tumor ECM is derived from the tumor cells in the main 
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part, with stromal contribution at different stages of metastasis (15).  Therefore, our findings 
suggest the ability of tumor cells to contribute to micro-environmental remodeling.  
 
Annexin A2 and Galectin-1 and their prognostic relevance in MM. 
ANXA2 and LGALS1, two ECM-affiliated proteins, were identified in newly diagnosed MM 
BM-ECMs, and not in healthy donor or MGUS BM-ECMs. We therefore analyzed the 
expression of ANXA2 and LGALS1 in MM cell lines, using the Cancer Cell Line 
Encyclopedia (CCLE); and found that both proteins were expressed in all MM cell lines (Fig. 
6A and 7A). These observations were further corroborated by demonstrating the higher 
expression of both ANXA2 and LGALS1 in BM MM- as compared to healthy donor-derived 
plasma cells (GSE2658 and GSE6477; Fig. 6B and 7B) (21) (25).  
Specifically, while ANXA2 levels were consistently higher in any given MGUS, smoldering-
MM, MM newly diagnosed or MM relapsed patient as compared to healthy donors, LGALS1 
was significantly higher in MGUS and newly diagnosed MM patients as compared to healthy 
individuals (Fig. 7B). 
In order to further understand if these targets may be leading to a permissive tumor 
microenvironment in MM, we analyzed the Mulligan dataset (26) for co-expression of these 
genes in MM using the publically available Oncomine resource (www.oncomine.org); we 
found that ANXA2 is one of the most highly co-expressed genes with LGALS1 in 264 MM 
patients (Fig. 8A; correlation coefficient = 0.522).  
We next interrogated the influence of both ANXA2 and LGALS1 in modulating survival in 
MM patients. By examining GSE2658 (27), and found that patients expressing higher levels 
of ANXA2 had a significantly reduced overall survival (OS) compared with those with lower 
expression levels (Fig. 8B; Log-rank p=4.9e-05). Similarly, high levels of LGALS1 were also 
associated with an inferior OS (Fig. 8C Log-rank P = 0.05)  
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DISCUSSION  
 
In this study, we report the profiling of the ECM composition of normal bone marrow using 
mass spectrometry. We have compared this profile to the composition of the ECM of patients 
with MGUS, newly diagnosed, and relapsed multiple myeloma.  
Our results demonstrate that significant remodeling of the bone marrow ECM is evident even 
at the MGUS stage, with loss of collagens and fibronectin (COL4A1-A3, COL4A6, 
COL5A2-3, COL6A2-3 COL10A1, COL11A2, COL16A1, COL27A1 and FN1). The 
absence of these proteins was consistent throughout the spectrum of MM from newly 
diagnosed to relapsed disease suggesting that the loss of these ECM components may 
contribute to a permissive tumor microenvironment supportive of the development and 
progression of MM. Indeed it has been shown that fibroblasts from patients with MGUS and 
MM demonstrate altered ECM profiles in comparison to those of healthy donors, supporting 
the hypothesis of early ECM remodeling (28).  
Similarly, some collagens and matrix metallo-proteinases found in healthy donor bone 
marrow are not detected at the MGUS stage but are seen to re-emerge in the disease 
progression pathway indicating that they may be more supportive in aggressive phenotypes. 
This includes, among others, COL1A1, COL1A2, COL3A1, COL5A1, MMP8 and MMP9. 
Interestingly, two proteins, Annexin A2 (ANXA2) and Galectin-1 (LGALS1) were detected 
in newly diagnosed MM but not in healthy donors or MGUS patients. These proteins were 
confirmed to be expressed in MM cell lines at the mRNA level in CCLE datasets. We 
hypothesized that these proteins may be required for myelomagenesis and further examined 
their presence in MM patient bone marrow.  
Our analysis of GEP profiles reveals that these proteins are highly expressed in MM bone 
marrow plasma cells in comparison to healthy-donor-derived plasma cells. This may indicate 
that these proteins are produced by the tumor cells within the bone marrow niche and are 
specific to the malignant phenotype. If this is the case, then plasma cells themselves may 
contribute to bone marrow ECM remodeling as has been shown in other tumors (15).  
Indeed, the galectins, of which LGALS1 is a member, are a family of beta-galactoside-
binding proteins implicated in modulating cell-cell and cell-matrix interactions and recently 
Galectin-1 suppression has been shown to inhibit MM induced angiogenesis and tumor 
growth in-vivo (29). Annexin A2 is a calcium dependent phospholipid binding protein, which 
plays a role in cell growth and heightens osteoclast formation and bone resorption. 
Osteoclasts are known to contribute to an immune suppressive microenvironment in MM and 
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are widely known to be associated with MM pathogenesis (30). Also, ANXA2 has previously 
been shown to promote MM cell growth and reduce apoptosis in MM cell lines (31). 
Identification of these targets, known to play a role in MM biology, helps to provide a wider 
validation of the remodeling of the ECM signature emerging using this novel strategy.  
To further understand the implications of bone marrow remodeling in MM patients, we 
examined if there might be a common expression pattern for these two proteins within the 
MM bone marrow niche. Using data from Oncomine, we analyzed 264 MM patients and 
found that ANXA2 is one of the most highly co-expressed genes with LGALS1 in these 
patients. This leads us to hypothesize that the bone marrow remodeling seen in MM is likely 
to be an organized process that occurs as a result of multiple ECM protein switches being 
turned on and off within the bone marrow niche. Although both of these markers have 
previously been identified as being important in MM, we have further validated them as 
being part of an overall ECM remodeling process within the bone marrow.  
The prognostic relevance of our findings was determined using GEP datasets, which provided 
survival outcomes for MM patients. This demonstrated that patients expressing higher levels 
of ANXA2 had a significantly reduced overall survival compared with those with lower 
expression levels. Similarly, high levels of LGALS1 were also associated with a shorter 
overall survival. This finding demonstrates that the bone marrow ECM plays an important 
role in MM and suggests that ECM remodeling is an active process within the bone marrow 
niche that has prognostic implications for MM patients. We can postulate that with the 
development of i) technologies to characterize the proteome and the matrisome with greater 
depth (including orthogonal peptide separation) and ii) methods to conduct quantitative 
analyses, we will be able to identify many more proteins, some of which may have prognostic 
values for MM patients. This previously under-evaluated area provides a potential resource 
for the identification of novel targets in this disease which may lead the way to preserving the 
normal ECM architecture and a less permissive niche.  
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FIGURE LEGENDS 
 
Figure 1. Staining of fibrillar collagens using Masson's trichrome (blue) of  mouse bone 
marrow samples.  
A. Healthy murine bone marrow. 
B. Multiple myeloma murine bone marrow. 
 
Figure 2. Staining of fibrillar collagens using Masson's trichrome (blue) of human bone 
marrow samples.  
A. Healthy human bone marrow. 
B. Multiple myeloma human bone marrow. 
 
Figure 3. Proteomic pipeline to characterize the ECM compoistion of normal and 
diseased bone marrow samples. 
A. Experimental pipeline. 
B. Western blot to control the efficiency of the decellularization of bone marrow samples. 
Western blot shows the depletion of intracellular components (GAPDH, histones, Transferrin 
receptor and vimentin) during the four-step decellularization process.  
Coomassie-stained gel shows the pattern of migration of proteins from the ECM-enriched 
samples. 
 
Figure 4. Comparison of the matrisome of normal and diseased bone marrow samples. 
A. Bar chart represents the number of proteins constituting the matrisome of normal, MGUS, 
newly diagnosed MM, and relapsed MM bone marrow. 
B. Venn diagram illustrated the overlap between the matrisome proteins detected in normal, 
MGUS, newly diagnosed MM, and relapsed MM bone marrow (Supplementary Table S2). 
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Figure 5. Gene set enrichment analysis of matrisome gene signature in MM patients. 
A. Gene set enrichment analysis (GSEA): demonstrating that (A) ECM proteins seen to be 
depleted in the bone marrow matrix with disease progression were also significantly down 
regulated at the gene level in normal donors (left) compared to MM patients (right). 
B. Heatmap demonstrating enrichment profile of relevant ECM genes in healthy donors vs. 
MM patients.  
Figure 6: Gene expression of ANXA2 in MM cell lines. 
A. Analysis of CCLE MM cell lines (red bars) demonstrating the expression ANXA2 in MM 
cell lines at the mRNA level.  
B. ANXA2 is significantly overexpressed at the mRNA level in MGUS, smoldering MM 
(SMM), newly diagnosed MM (MM, ndx) and relapsed MM (MM relapse) in comparison to 
normal donors (ND). Dataset reference: Cancer Res. 2007 Apr 1;67(7):2982-9. (GSE6477) 
 
Figure 7: Gene expression of LGALS1 in MM cell lines. 
A. LGALS1 is also significantly overexpressed at the mRNA level in newly diagnosed MM 
patients compared to normal donors in CCLE dataset.   
B. LGALS1 is significantly overexpressed at the mRNA level in MGUS, smoldering MM 
(SMM), newly diagnosed MM (MM, ndx) and relapsed MM (MM relapse) in comparison to 
normal donors (ND). Dataset reference: Cancer Res. 2007 Apr 1;67(7):2982-9. (GSE6477) 
 
Figure 8. Expression of ECM proteins in MM patients and impact on overall survival. 
A. Co-expression of LGALS1 and ANXA2 in MM patients – data sourced from Oncomine 
(www.oncomine.org) Mulligan MM gene expression Blood. 2007 Apr 15;109(8):3177-88. 
Epub 2006 Dec 21. 
B. Kaplan-Meier survival proportions analysis of patient outcome data from the GSE2658 
MM GEP dataset demonstrating high levels of ANXA2 expression associated with inferior 
overall survival. Log-rank P = 4.9e-05 
C. Kaplan-Meier survival proportions analysis of patient outcome data from the GSE2658 
MM GEP dataset demonstrating high levels of LGALS1 expression associated with inferior 
overall survival. Log-rank P = 0.051. 
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Supplementary Table S1. Bone marrow matrisome. Matrisome of the bone marrow from 
healthy donors (A), MGUS patients (B), newly diagnosed multiple myeloma patients (C), and 
relapsed multiple myeloma patients (D). * indicates ECM or ECM-associated proteins not 
detected before in any human tissue matrisome. 
 
Supplementary Table S2. Comparison of the matrisome of normal, MGUS, newly 
diagnosed MM, and relapsed MM bone marrow 
Supplementary Table S3.  Proteomic data 
A.  Complete proteomic dataset. Proteins are sorted by matrisome categories and then by 
Entrez Gene Symbol. 
B-E. The total precursor-ion intensity, number of spectra and unique peptides were calculated 
for each protein and in each sample. Proteins are sorted by number of observations (column 
D), then matrisome categories (column B) and gene symbols (column C). Proteins detected in 
at least 3 patients and with at least 3 peptides in one of the samples compose the matrisome 
of each of the four bone marrow sample types (bold). 
B. All ECM and ECM-associated proteins detected in normal bone marrow samples.  
C. All ECM and ECM-associated proteins detected in bone marrow samples from MGUS 
samples.  
D. All ECM and ECM-associated proteins detected in bone marrow samples from newly 
diagnosed multiple myeloma patients.  
E. All ECM and ECM-associated proteins detected in bone marrow samples from relapsed 
multiple myeloma patients.  
F. Name of raw mass spectrometry files.  
 
Supplementary Figure 1: Proteomic metrics.  
Pie charts represent relative amount of core matrisome (blue), matrisome-associated (orange) 
and other (grey) proteins in terms of peptide abundance, and numbers of spectra, unique 
peptides and proteins. 
A. Metrics for representative normal bone marrow sample. 
B. Metrics for representative MGUS sample. 
C. Metrics for representative newly diagnosed multiple myeloma sample. 
D. Metrics for representative relapsed multiple myeloma sample. 
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Supplementary Figure 2: ECM peptide abundance 
Bar charts represent the peptide abundance for ECM vs non-ECM proteins (A) and for core 
matrisome and matrisome-associated proteins (B) in each sample analyzed. 
 








